PH12018502226A1 - Orally disintegrating tablets - Google Patents

Orally disintegrating tablets

Info

Publication number
PH12018502226A1
PH12018502226A1 PH12018502226A PH12018502226A PH12018502226A1 PH 12018502226 A1 PH12018502226 A1 PH 12018502226A1 PH 12018502226 A PH12018502226 A PH 12018502226A PH 12018502226 A PH12018502226 A PH 12018502226A PH 12018502226 A1 PH12018502226 A1 PH 12018502226A1
Authority
PH
Philippines
Prior art keywords
disintegrating tablets
orally disintegrating
rapidly disintegrating
oral dosage
disintegrating
Prior art date
Application number
PH12018502226A
Other languages
English (en)
Inventor
Husban Farhan Abdel Karim Mohammad Al
Lars H†Kan Christer Glad
Jenny Malin Christina Hallstein
Andrea Jane Moir
Michael Peter Thompson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58640851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12018502226(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PH12018502226A1 publication Critical patent/PH12018502226A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12018502226A 2016-04-21 2018-10-18 Orally disintegrating tablets PH12018502226A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325584P 2016-04-21 2016-04-21
PCT/EP2017/059443 WO2017182589A1 (en) 2016-04-21 2017-04-20 Orally disintegrating tablets

Publications (1)

Publication Number Publication Date
PH12018502226A1 true PH12018502226A1 (en) 2019-07-29

Family

ID=58640851

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502226A PH12018502226A1 (en) 2016-04-21 2018-10-18 Orally disintegrating tablets

Country Status (26)

Country Link
US (1) US10729655B2 (enExample)
EP (2) EP4417537A3 (enExample)
JP (2) JP6960941B2 (enExample)
KR (2) KR102488486B1 (enExample)
CN (3) CN107595789B (enExample)
AU (2) AU2017253367B2 (enExample)
BR (1) BR112018071440A2 (enExample)
CO (1) CO2018012431A2 (enExample)
DK (1) DK3445338T3 (enExample)
EA (1) EA201892150A1 (enExample)
ES (1) ES3014055T3 (enExample)
FI (1) FI3445338T3 (enExample)
HR (1) HRP20250204T1 (enExample)
HU (1) HUE070095T2 (enExample)
IL (1) IL262312B (enExample)
LT (1) LT3445338T (enExample)
MA (1) MA44720B1 (enExample)
PE (1) PE20190372A1 (enExample)
PH (1) PH12018502226A1 (enExample)
PL (1) PL3445338T3 (enExample)
PT (1) PT3445338T (enExample)
RS (1) RS66536B1 (enExample)
SG (2) SG10202107682QA (enExample)
SI (1) SI3445338T1 (enExample)
SM (1) SMT202500081T1 (enExample)
WO (1) WO2017182589A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法
CN109700773B (zh) * 2019-03-01 2021-03-16 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛制剂组合物及其制备方法
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
CN114712317A (zh) * 2021-01-04 2022-07-08 弘和制药有限公司 一种替格瑞洛药物组合物及其制备方法和其应用
US20220387328A1 (en) 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
KR20240089377A (ko) * 2021-10-04 2024-06-20 뉴림 파머슈티칼스(1991) 리미티드 자폐 스펙트럼 장애를 갖는 대상체를 치료하기 위한 방법 및 생성물
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
CN116370423B (zh) * 2023-02-28 2024-11-12 天津力生制药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
CA2419290C (en) * 2001-05-10 2007-03-27 Yuuki Takaishi Quick-disintegrating tablet in the buccal cavity and manufacturing method thereof
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CN2717851Y (zh) 2004-05-14 2005-08-17 重庆康刻尔制药有限公司 一种药品包装板
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
FR2968992B1 (fr) 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
US20130160408A1 (en) * 2011-12-22 2013-06-27 Gregor N. Neff Blister Pack and Method
WO2013115171A1 (ja) 2012-02-03 2013-08-08 旭化成ケミカルズ株式会社 苦味マスク顆粒含有口腔内崩壊錠
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103964066B (zh) * 2013-02-06 2017-09-19 李和伟 一种冻干赋型制剂的包装装置
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104650091B (zh) 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
EA201691582A1 (ru) * 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты

Also Published As

Publication number Publication date
EP3445338B1 (en) 2024-11-27
IL262312A (en) 2018-11-29
MA44720B1 (fr) 2025-02-28
SG10202107682QA (en) 2021-08-30
SI3445338T1 (sl) 2025-03-31
US20190117577A1 (en) 2019-04-25
EA201892150A1 (ru) 2019-05-31
CN107595789A (zh) 2018-01-19
LT3445338T (lt) 2025-02-25
PT3445338T (pt) 2025-03-03
WO2017182589A9 (en) 2018-04-19
RS66536B1 (sr) 2025-03-31
JP2022009050A (ja) 2022-01-14
JP2019516674A (ja) 2019-06-20
AU2020201930B2 (en) 2020-10-29
HK1249732A1 (zh) 2018-11-09
MA44720A (fr) 2019-02-27
SG11201808996SA (en) 2018-11-29
FI3445338T3 (fi) 2025-01-29
SMT202500081T1 (it) 2025-03-12
CO2018012431A2 (es) 2018-11-30
HUE070095T2 (hu) 2025-05-28
HK1248562A1 (zh) 2018-10-19
AU2017253367A1 (en) 2018-11-08
CN107595790A (zh) 2018-01-19
EP4417537A3 (en) 2024-12-04
IL262312B (en) 2022-08-01
WO2017182589A1 (en) 2017-10-26
US10729655B2 (en) 2020-08-04
CN107595789B (zh) 2021-01-15
AU2017253367B2 (en) 2020-04-16
BR112018071440A2 (pt) 2019-02-05
KR102488486B1 (ko) 2023-01-12
KR20220054907A (ko) 2022-05-03
DK3445338T3 (da) 2025-02-10
KR102392347B1 (ko) 2022-05-02
AU2020201930A1 (en) 2020-04-09
KR20180132147A (ko) 2018-12-11
PE20190372A1 (es) 2019-03-08
CN107595790B (zh) 2021-01-12
JP6960941B2 (ja) 2021-11-05
EP3445338A1 (en) 2019-02-27
HRP20250204T1 (hr) 2025-04-11
JP7254871B2 (ja) 2023-04-10
CN107530288A (zh) 2018-01-02
PL3445338T3 (pl) 2025-03-31
ES3014055T3 (en) 2025-04-16
CN107530288B (zh) 2022-01-25
EP4417537A2 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
PH12018502226A1 (en) Orally disintegrating tablets
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2011002955A1 (es) Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades.
MX347040B (es) Inhibidores de tirosina-cinasas.
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
EA201590745A1 (ru) Твердая пероральная фармацевтическая композиция, содержащая тикагрелор
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
CL2013000933A1 (es) Compuestos derivados de furo[3,2-d]pirimidina y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una afeccion que esta mediada por la actividad de una proteina quinasa, tal como cancer, trastornos cardiovasculares, del snc e inmunes, y enfermedades relacionadas con la inmunodeficiencia adquirida.
EP3107914B8 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
SI3418281T1 (sl) Pirazolo(1,5-A)pirimidini, uporabni kot zaviralci kinaze ATR za zdravljenje rakavih obolenj
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
EP4309736A3 (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide
MX368112B (es) Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2018119395A8 (en) Compounds, compositions and methods of use
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
ES2636936T3 (es) Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
USD769119S1 (en) Cover
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
MX377489B (es) Compuesto de pirazolo[1,5-a]pirimidina.
SI3596080T1 (sl) Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati
WO2016032209A3 (ko) 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민
IL234966A0 (en) Crystal forms of (4-(s-amino-4)-1)-n-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo [3,2-d]pyrimidin-4-yl)piperidine-4-carboxamide
EA024825B8 (ru) Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение
MY194359A (en) Orally disintegrating tablets